Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Mallinckrodt
Argus Health
Medtronic
Fuji
Harvard Business School

Generated: August 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,738,905

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,738,905
Title:Vector for expressing NC protein of HIV and method for producing NC protein using the same
Abstract: The present invention relates to a vector for expressing an NC protein of HIV and a method for producing an NC protein using the same. More particularly, the present invention relates to a vector for expressing an NC protein of HIV, in which an intron sequence and an mRNA stability element in the downstream of NC gene are sequentially linked, and a method for producing an NC protein using the same. The vector for expressing an NC protein of HIV of the present invention, in which an intron sequence and an mRNA stability element in the downstream of NC gene are sequentially linked, can express a wild type NC protein in animal cells, and has an effect of improving the expression efficiency, as compared to a known art.
Inventor(s): You; Ji Chang (Seoul, KR)
Assignee: You; Ji Chang (Seoul, KR) AVIXGEN INC. (Seoul, KR)
Application Number:12/520,147
Patent Claims:1. A vector for expressing a nucleocapsid (NC) protein of Human Immunodeficiency Virus (HIV), comprising a) any one sequence selected from the group consisting of an SV40 19s mRNA intron sequence of SEQ ID NO:8, a modified SV40 16S mRNA intron sequence of SEQ ID NO:9 and a .beta.-globin intron sequence of SEQ ID NO: 10, b) a gene encoding for an HIV NC protein of SEQ. ID NO. 4, selected from the group consisting of SEQ ID NO:3, 5, 6 AND 7, and c) an mRNA stability element wherein the genes of a)-c) are sequentially linked.

2. The vector for expressing an NC protein of HIV according to claim 1, wherein the mRNA stability element is any one selected from the group consisting of RRE (Rev response element), WPRE (woodchuck post-transcriptional regulatory element), .beta.-actin 3'-UTR (untranslated regions) and RSV stability element (Rous sarcoma virus stability element).

3. The vector according to claim 1, wherein the vector for expressing an NC protein of HIV has a cleavage map disclosed in FIG. 2 or FIG. 4.

4. An isolated cell transformed with the vector of any one of claim 2, or 3.

5. The transformed cell according to claim 4, wherein the cell is a COS-7 or 293T cell.

6. A method for producing an NC protein of HIV, comprising the step of culturing the transformed cell of claim 4.

7. A codon-optimized HIV NC polynucleotide for high expression in mammalian cells, comprising a nucleotide sequence represented by any one selected from the group consisting of SEQ. ID NO. 3, SEQ. ID NO. 5, SEQ. ID NO. 6 and SEQ. ID NO. 7.

Summary for Patent:   Try a Free Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
South Korea10-2006-0131392Dec 20, 2006
South Korea10-2006-0131393Dec 20, 2006
PCT Information
PCT FiledDecember 20, 2007PCT Application Number:PCT/KR2007/006694
PCT Publication Date:June 26, 2008PCT Publication Number:WO2008/075911

Details for Patent 9,738,905

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Try a Free Trial You; Ji Chang (Seoul, KR) AVIXGEN INC. (Seoul, KR) 2026-12-20 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Try a Free Trial You; Ji Chang (Seoul, KR) AVIXGEN INC. (Seoul, KR) 2026-12-20 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Try a Free Trial You; Ji Chang (Seoul, KR) AVIXGEN INC. (Seoul, KR) 2026-12-20 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
McKinsey
Express Scripts
Mallinckrodt
Medtronic
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.